Sadly, despite earlier reports of (slight) efficacy this study found that treatment with Tilavonemab wasn't significantly better than placebo.

>A total of 453 patients were randomized, of whom 337 were treated with tilavonemab (300 mg, n = 108; 1000 mg, n = 116; 2000 mg, n = 113) and 116 received placebo. Baseline demographics and disease characteristics were comparable across groups. The mean age was 71.3 (standard deviation [SD] 7.0) years, 51.7% were female, and 96.5% were White. At baseline, the mean CDR-SB score was 3.0 (1.2), which worsened through Week 96 for all treatment groups. The least squares mean change from baseline at Week 96 in the CDR-SB score with tilavonemab was not significantly different compared with placebo (300 mg [n = 85]: −0.07 [95% confidence interval (CI): –0.83 to 0.69]; 1000 mg [n = 91]: −0.06 [95% CI: –0.81 to 0.68]; 2000 mg [n = 81]: 0.16 [95% CI: –0.60 to 0.93]; all P ≥ 0.05). The incidence of any adverse event and MRI findings were generally comparable across groups.Tilavonemab was generally well tolerated but did not demonstrate efficacy in treating patients with early Alzheimer’s disease. Further investigations of tilavonemab in early Alzheimer’s disease are not warranted.